Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: From the investigation on nutrition status and clinical outcome of common cancers study
Ming Yang(Jiangsu University), Hanping Shi(Beijing Shijitan Hospital), Guo‐Tian Ruan(Beijing Friendship Hospital), Shiqi Lin(Nanjing University of Information Science and Technology), Qin‐Qin Li(Capital Medical University), Chunlei Hu(Capital Medical University), Kang‐Ping Zhang(Capital Medical University), Hailun Xie(Guangxi Medical University), Mengmeng Song(China Pharmaceutical University), Heyang Zhang(Academy of Military Medical Sciences), Chenan Liu(Hunan University of Technology), Qi Zhang(University of Electronic Science and Technology of China), Tong Liu(Second Hospital of Tianjin Medical University), Yue Chen(Capital Medical University), Xin Zheng(RMIT University), Xi Zhang(Shanghai Jiao Tong University), Xiangrui Li(Institute of Plant Protection), Yuying Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ziwen Wang(Shanghai Children's Medical Center), Xiaoyue Liu(Zhejiang University), Xiaowei Zhang(Shanghai Medical College of Fudan University), Yi‐Zhong Ge(China International Science and Technology Cooperation), Meng Tang(Capital Medical University)
Cited by 189
Related Papers
The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer
|Journal of Cachexia Sarcopenia and Muscle|2022|170
A1 astrocytes contribute to murine depression-like behavior and cognitive dysfunction, which can be alleviated by IL-10 or fluorocitrate treatment
|Journal of Neuroinflammation|2020|167
A Novel Inflammation and Insulin Resistance Related Indicator to Predict the Survival of Patients With Cancer
|Frontiers in Endocrinology|2022|161
Inflammatory burden as a prognostic biomarker for cancer
|Clinical Nutrition|2022|152
Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
|Journal of Experimental & Clinical Cancer Research|2024|141